<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238965</url>
  </required_header>
  <id_info>
    <org_study_id>3C-08-1</org_study_id>
    <secondary_id>NCI-2010-02149</secondary_id>
    <nct_id>NCT01238965</nct_id>
  </id_info>
  <brief_title>Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy</brief_title>
  <official_title>Phase I Clinical Trial With LBH589 and Infusional 5-FU/LV in Patients With Metastatic Colorectal Cancer Who Failed 5-FU Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for&#xD;
      cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving panobinostat together with fluorouracil and leucovorin calcium may&#xD;
      kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and the best&#xD;
      dose of giving panobinostat, fluorouracil, and leucovorin calcium together in treating&#xD;
      patients with stage IV colorectal cancer who did not respond to previous fluorouracil-based&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety and feasibility of combining LBH589 with infusional 5-FU&#xD;
      chemotherapy in the treatment of Stage IV colorectal cancer patients who have progressed on&#xD;
      standard 5-FU regimens.&#xD;
&#xD;
      II. To determine the efficacy of LBH589 alone to produce consistent decreases in tumor&#xD;
      thymidylate synthase (TS) expression.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the time to tumor progression, progression free and overall survival of&#xD;
      patients with advanced or metastatic colorectal cancer treated with LBH589 combined with&#xD;
      infusional 5-FU.&#xD;
&#xD;
      II. To determine if TS repression by LBH589 predicts response to the combination of LBH589&#xD;
      and infusional 5-FU in patients who have already progressed on standard regimens containing&#xD;
      5-FU.&#xD;
&#xD;
      III. To obtain preliminary data on gene expression levels of TS, DPD and TP as well as&#xD;
      germline polymorphisms of TS being associated with clinical outcome and toxicity.&#xD;
&#xD;
      IV. To obtain preliminary data on acetylation on peripheral blood mononuclear cells to&#xD;
      establish biological activity in these patients at time of biopsies.&#xD;
&#xD;
      OUTLINE: Patients receive oral panobinostat 3 times a week. Patients also receive leucovorin&#xD;
      calcium IV over 2 hours on days 1 and 15 followed by fluorouracil IV continuously over 46&#xD;
      hours on days 1-2 and 15-16. Courses repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity. After completion of study treatment, patients are&#xD;
      followed up every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Adverse Events&#xD;
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety of this regimen</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>At 3, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Every 2 months until disease recurrence or progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 3, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral panobinostat 3 times a week. Patients also receive leucovorin calcium IV over 2 hours on days 1 and 15 followed by fluorouracil IV continuously over 46 hours on days 1-2 and 15-16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panobinostat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Faridak</other_name>
    <other_name>HDAC inhibitor LBH589</other_name>
    <other_name>histone deacetylase inhibitor LBH589</other_name>
    <other_name>LBH589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Efudex</other_name>
    <other_name>FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>calcium folinate</other_name>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>citrovorum factor</other_name>
    <other_name>LV</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>RT-PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Blotting, Western</other_name>
    <other_name>Western Blot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed advanced/metastatic&#xD;
             colorectal cancer&#xD;
&#xD;
          -  Must have measurable disease&#xD;
&#xD;
          -  Must have received prior therapy (in any setting) with 5-FU, CPT-11, and oxaliplatin;&#xD;
             (may have received prior erbitux and bevacizumab, but it is not required)&#xD;
&#xD;
          -  Must have received at least one prior chemotherapy regimen for advanced disease&#xD;
&#xD;
          -  Tumor must be accessible for core biopsy at the beginning of treatment and patients&#xD;
             have a high intratumoral TS expression level prior to the beginning of treatment&#xD;
&#xD;
          -  Life expectancy of &gt; 12 weeks&#xD;
&#xD;
          -  ECOG performance status 0-2 (Karnofsky &gt;= 50%)&#xD;
&#xD;
          -  Normal organ and marrow function as defined below:&#xD;
&#xD;
          -  Serum albumin &gt;= 3g/dL&#xD;
&#xD;
          -  AST/SGOT and ALT/SGPT =&lt; 2.5 x upper limit of normal(ULN)or =&lt; 5.0 x ULN if the&#xD;
             transaminase elevation is due to liver metastasis&#xD;
&#xD;
          -  Serum bilirubin =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN or 24-hr creatinine clearance &gt;= 50 ml/min&#xD;
&#xD;
          -  Serum potassium &gt;= LLN&#xD;
&#xD;
          -  Serum phosphorous &gt;= LLN&#xD;
&#xD;
          -  Serum total calcium (corrected for serum albumin) or serum ionized calcium &gt;= LLN&#xD;
&#xD;
          -  Serum magnesium &gt;= LLN&#xD;
&#xD;
          -  TSH and free T4 within normal limits(WNL)(patients may be on thyroid hormone&#xD;
             replacement)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/μL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/μL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/μL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 mg/dL&#xD;
&#xD;
          -  Eligibility of patients receiving any medications or substances known to affect or&#xD;
             with the potential to affect the activity or pharmacokinetics of LBH589 will be&#xD;
             determined following review by the Principal Investigator&#xD;
&#xD;
          -  Ability to understand and willing to sign a written informed consent document&#xD;
&#xD;
          -  INR is =&lt; 1.5 times ULN unless receiving therapeutic anticoagulation&#xD;
&#xD;
          -  Patient is highly unlikely to conceive as indicated by at least one &quot;yes&quot; answer to&#xD;
             the following questions:&#xD;
&#xD;
               1. patient is a male and agrees to use an adequate method of contraception for the&#xD;
                  duration of the study, and for 30 days after the last dose of study medication;&#xD;
&#xD;
               2. surgically sterilized female;&#xD;
&#xD;
               3. postmenopausal female &gt;= 45 years of age with &gt; 2 years since last menses;&#xD;
&#xD;
               4. non-sterilized premenopausal female and agrees to use 2 adequate barrier methods&#xD;
                  of contraception to prevent pregnancy or agrees to abstain from heterosexual&#xD;
                  activity throughout the study and for 30 days after the last dose of study&#xD;
                  medication&#xD;
&#xD;
          -  Baseline MUGA must demonstrate LVEF &gt;= the lower limit of the institutional normal&#xD;
&#xD;
          -  Clinically euthyroid; Note: Patients are permitted to receive thyroid hormone&#xD;
             supplements to treat underlying hypothyroidism&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male patients whose sexual partners are WOCBP not using effective birth control&#xD;
&#xD;
          -  May not have received any other investigational agents within 28 days of study entry&#xD;
             (chemotherapy, any investigational drug or undergone major surgery &lt; 4 weeks prior to&#xD;
             starting study drug or who have not recovered from side effects of such therapy).&#xD;
&#xD;
          -  May not receive other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal&#xD;
             other than for replacement) while on this study&#xD;
&#xD;
          -  Patients with known brain metastases are excluded from this clinical trial&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to LBH589; including sodium butyrate, trichostatin A (TSA), trapoxin&#xD;
             (TPX), MS-27-275 and depsipeptide&#xD;
&#xD;
          -  Severe and/or uncontrolled intercurrent illness including, but not limited to, ongoing&#xD;
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements&#xD;
&#xD;
          -  Pregnant or breast feeding or patients of reproductive potential not using two&#xD;
             effective methods of birth control; women of childbearing potential (WOCBP) must have&#xD;
             a negative serum pregnancy test within 7 days of the first administration of oral&#xD;
             LBH589&#xD;
&#xD;
          -  History of another primary malignancy within 5 years other than curatively treated CIS&#xD;
             of the cervix, or basal or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Unresolved diarrhea &gt; CTCAE grade 1&#xD;
&#xD;
          -  Acute infection requiring intravenous antibiotic, antiviral, or antifungal medications&#xD;
             within 2 weeks prior to the start of study drugs&#xD;
&#xD;
          -  Known positivity for human immunodeficiency virus (HIV) or hepatitis C&#xD;
&#xD;
          -  Screening ECG with a QTc &gt; 450 msec&#xD;
&#xD;
          -  Patients with congenital long QT syndrome&#xD;
&#xD;
          -  History of sustained ventricular tachycardia&#xD;
&#xD;
          -  Any history of ventricular fibrillation or torsades de pointes&#xD;
&#xD;
          -  Bradycardia defined as heart rate &lt; 50 beats per minute; patients with a pacemaker and&#xD;
             heart rate &gt;= 50 beats per minute are eligible&#xD;
&#xD;
          -  Myocardial infarction or unstable angina within 6 months of study entry&#xD;
&#xD;
          -  Congestive heart failure (NY Heart Association class III or IV)&#xD;
&#xD;
          -  Right bundle branch block and left anterior hemiblock (bifascicular block)&#xD;
&#xD;
          -  Prior cancer treatment with an HDAC inhibitor (e.g., vorinostat, Depsipeptide, MS-275,&#xD;
             LAQ-824, PXD-101, and valproic acid)&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Concomitant use of drugs with a risk of causing torsades de pointes&#xD;
&#xD;
          -  Any significant history of non-compliance to medical regimens or with inability to&#xD;
             grant a reliable informed consent&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of oral panobinostat (e.g., ulcerative disease, uncontrolled&#xD;
             nausea, vomiting, diarrhea, malabsorption syndrome, obstruction, or stomach and/or&#xD;
             small bowel resection)&#xD;
&#xD;
          -  Patients needing valproic acid for any medical condition during the study or within 5&#xD;
             days prior to first LBH589&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz-Josef Lenz</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

